Core Insights - Some of the best dividend stocks, including Federal Realty Investment Trust, Johnson & Johnson, and PepsiCo, are currently experiencing significant price declines, making them attractive investment opportunities due to higher dividend yields [1][12] Federal Realty Investment Trust - Shares have declined nearly 20% from their 52-week high, resulting in a dividend yield exceeding 4.5%, which is over three times higher than the S&P 500's sub-1.5% yield [2] - The company has a record of increasing dividends for 57 consecutive years, the longest in the REIT industry, qualifying it as a Dividend King [4] - Federal Realty focuses on high-quality retail properties in major metro markets, particularly open-air shopping centers and mixed-use properties, leading to high occupancy and steady rent growth [5] Johnson & Johnson - Shares have dropped more than 8% from their recent peak, raising the dividend yield to nearly 3.5% [6] - The company has increased its dividend payment by 4.8% this year, extending its growth streak to 63 consecutive years [6] - Johnson & Johnson holds a AAA credit rating, with a strong balance sheet and robust free cash flow, generating about $20 billion annually, which comfortably covers its nearly $12 billion dividend outlay [7][8] PepsiCo - The stock has fallen over 27% from its 52-week high, resulting in a dividend yield surpassing 4% [9] - PepsiCo recently increased its dividend payout by 5%, extending its growth streak to 53 consecutive years [9] - The company invests heavily in product development and capacity expansion, expecting 4% to 6% annual organic revenue growth and high single-digit earnings-per-share growth [10][11]

Company Overview - Johnson & Johnson is represented by Chairman and CEO Joaquin Duato and CFO Joseph Wolk during the Bernstein's 41st Annual Strategic Decisions Conference [1][3] - The company has a long-standing presence in the industry, with Duato noting his participation in all strategic decision conferences since becoming CEO [5] Industry Insights - The industry is experiencing significant medical innovation driven by a combination of science and technology, which is viewed as unprecedented in the last 40 years [5] - There are numerous opportunities to improve the standard of care, indicating a healthy state for the industry [5]

Johnson & Johnson (JNJ) FY 2025 Conference May 28, 2025 09:00 AM ET Speaker0 Alright. Thank you, everybody. Thanks, guys. I'm Lee Hambrite, US med tech analyst at Bernstein, and we are thrilled to host Johnson and Johnson. We have chairman and CEO, Joaquin Guato, and CFO, Joe Wall. Guys, for being here. Speaker1 Thank you. Thanks for having us. Speaker0 So we're scheduled for a fifty minute fireside chat. Just a reminder that investors can submit questions at any time through Pigeonhole, and we'll try to wo ...

思宇年度活动回顾： 首届全球眼科大会 | 首届全球骨科大会 | 首届全球心血管大会 即将召开： 2025年6月12日，首届全球医美科技大会 2025年7月17日，第二届全球医疗科技大会 2025年9月4-5日，第三届全球手术机器人大会 2025年 5月21日， 强生医疗科技 （Johnson & Johnson MedTech）宣布旗下 Biosense Webster 公司 新一代心腔内超声成像（ICE）导管 —— SOUNDSTAR CRYSTAL 已正式在美国上市，用于心 脏消融手术中的高分辨率ICE成像 。 SOUNDSTAR CRYSTAL 集成了 88 单元相控阵列 、 AI 三维重建 等尖端技术， 作为强生 SOUNDSTAR 第 3 代以及旗舰 ICE 产品 ，它的 上市进一步巩固了强生在全球心脏电生理及介入超声领 域的技术领先地位，标志着强生在心脏电生理介入领域的又一重大技术升级，进一步完善了其超声解决方 案组合。 2024 年 12 月 10 日，全球首例 SOUNDSTAR CRYSTAL 商业应用手术在德州奥斯汀完成。该手术将 SOUNDSTAR CRYSTAL 导管与 CARTO 3 ...

I am focused on growth and dividend income. My personal strategy revolves around setting myself up for an easy retirement by creating a portfolio which focuses on compounding dividend income and growth. Dividends are an intricate part of my strategy as I have structured my portfolio to have monthly dividend income which grows through dividend reinvestment and yearly increases. Feel free to reach out to me on Seeking AlphaAnalyst’s Disclosure: I/we have no stock, option or similar derivative position in any ...

Core Insights - The article highlights the attractiveness of dividend-paying stocks within the Dow Jones Industrial Average, specifically focusing on Chevron, Johnson & Johnson, and Verizon as top choices for passive income in 2025 and beyond [2][13]. Chevron - Chevron currently offers a dividend yield of over 5%, significantly higher than the average yield of Dow components, which is below 2% [4]. - The company has a strong track record of increasing dividends for 38 consecutive years, demonstrating resilience through various commodity cycles [5]. - Chevron's breakeven level is around $30 per barrel, and it expects to boost free cash flow by $9 billion next year, assuming oil prices average $60 per barrel [6]. Johnson & Johnson - Johnson & Johnson's dividend yield is approximately 3.4%, with a recent increase of nearly 5%, extending its dividend growth streak to 63 years [7]. - The company holds an AAA bond rating and has a net debt of $13.5 billion against a market cap of $370 billion, indicating a strong financial position [8]. - In the previous year, Johnson & Johnson generated $20 billion in free cash flow, covering its $11.8 billion dividend outlay while investing over $17 billion in R&D [9]. Verizon - Verizon boasts the highest dividend yield in the Dow at 6.2%, supported by $36.9 billion in cash flow from operations [10]. - The company is acquiring Frontier Communications for $20 billion, which is expected to enhance its fiber network and yield annual cost savings of at least $500 million [11]. - Verizon has delivered its 18th consecutive annual dividend increase, maintaining the longest current payout-hiking streak in the U.S. telecom sector [12].

Company Overview - Johnson & Johnson (JNJ) ended the latest trading session at $152.51, reflecting a -0.44% adjustment from the previous day's close, underperforming the S&P 500 which had a daily loss of 0.04% [1] - The stock has decreased by 1.42% over the past month, while the Medical sector gained 1.44% and the S&P 500 increased by 13.42% [1] Upcoming Financial Results - Analysts expect Johnson & Johnson to report earnings of $2.65 per share, indicating a year-over-year decline of 6.03% [2] - The consensus estimate for revenue is $22.77 billion, representing a 1.42% increase from the prior-year quarter [2] Annual Forecast - Zacks Consensus Estimates project earnings of $10.60 per share and revenue of $91.19 billion for the entire year, showing changes of +6.21% and +2.66% respectively compared to the previous year [3] - Recent revisions in analyst estimates are crucial as they reflect near-term business trends, with positive revisions indicating optimism about the company's profitability [3] Valuation Metrics - Johnson & Johnson is currently trading at a Forward P/E ratio of 14.45, which is a premium compared to the industry average Forward P/E of 13.21 [6] - The company has a PEG ratio of 2.32, while the Large Cap Pharmaceuticals industry has an average PEG ratio of 1.21 [6] Industry Context - The Large Cap Pharmaceuticals industry, part of the Medical sector, holds a Zacks Industry Rank of 40, placing it in the top 17% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Core Viewpoint - Johnson & Johnson (J&J) is facing multiple challenges including declining sales in its MedTech segment, loss of exclusivity for its drug Stelara, and ongoing talc lawsuits, while also navigating a volatile macroeconomic environment [1][2][26] Company Strengths and Weaknesses - J&J's diversified business model is a significant strength, operating through pharmaceuticals and medical devices with over 275 subsidiaries, which helps it withstand economic cycles [4] - The separation of its Consumer Health business into Kenvue allows J&J to focus on its core pharmaceutical and medical device operations [5] Innovative Medicine Unit - J&J's Innovative Medicine unit is experiencing growth, with sales increasing by 4.4% in Q1 2025 despite the loss of exclusivity for Stelara [6] - The company anticipates generating over $57 billion in sales from the Innovative Medicines segment in 2025, with expected growth of 5-7% from 2025 to 2030 [7] - J&J has identified 10 new products with potential peak sales of $5 billion, including cancer drugs and pipeline candidates [8] Patent Expiration and Sales Impact - The loss of U.S. patent exclusivity for Stelara in 2025 is expected to significantly impact sales, which were $10.36 billion in 2024, with a projected decline of 33.7% in Q1 2025 [9][10] - The introduction of biosimilars is anticipated to further erode Stelara's sales throughout 2025 [11] MedTech Segment Challenges - J&J's MedTech sales are facing headwinds, particularly in the Asia Pacific region, with challenges from China's volume-based procurement program and competitive pressures [12][13] - No improvement is expected in the Asia Pacific region for 2025, with ongoing impacts from the VBP program [13] Legal Issues - J&J is dealing with over 62,000 lawsuits related to its talc-based products, which allege that these products contain asbestos [14] - A bankruptcy court recently rejected J&J's proposed plan to settle these lawsuits, forcing the company to revert to traditional legal proceedings [15] Stock Performance and Valuation - J&J's stock has outperformed the industry year-to-date, rising 6.8% compared to a 2.7% decline in the industry [16] - The stock is reasonably priced with a price/earnings ratio of 14.25, slightly below the industry average of 14.79 [19] Future Outlook - J&J considers 2025 a "catalyst year" for growth, expecting operational sales growth to accelerate in the second half of the year [24] - The company has a promising R&D pipeline and has recently made acquisitions to strengthen its market position [25]

证券研究报告 | 2025年05月21日 海外制药企业2025Q1业绩回顾 ——美国药品价格改革叠加不确定的宏观环境 行业研究 · 行业专题 医药生物 投资评级：优于大市（维持评级） 证券分析师：马千里 010-88005445 maqianli@guosen.com.cn S0980521070001 证券分析师：陈曦炳 0755-81982939 chenxibing@guosen.com.cn S0980521120001 证券分析师：彭思宇 0755-81982723 pengsiyu@guosen.com.cn S0980521060003 请务必阅读正文之后的免责声明及其项下所有内容 摘要 请务必阅读正文之后的免责声明及其项下所有内容 2 ◼ Pharma收入端增长整体有所放缓：2025Q1，礼来及诺和诺德在GLP-1类药物驱动下，收入端分别+45%/+18%，其中诺和诺德由于美 国compounded GLP-1药物影响，销售低于预期并下调全年收入指引；诺华、艾伯维、阿斯利康、赛诺菲分别依靠诺欣妥/可善挺、 Skyrizi/Rinvoq、Farxiga/Enhertu、Dupixent等核心品种 ...

Core Insights - The FDA Oncologic Drugs Advisory Committee (ODAC) voted 6-2 in favor of the benefit-risk profile of DARZALEX FASPRO® for treating high-risk smoldering multiple myeloma (HR-SMM), marking a significant step in the treatment landscape for this condition [1][2][3] Company Insights - Johnson & Johnson aims to transform oncology care by advocating for early intervention in high-risk smoldering multiple myeloma, potentially delaying or preventing progression to active multiple myeloma [4][6] - The company emphasizes its commitment to evolving treatment paradigms for multiple myeloma, aligning with its vision for a future where early diagnosis and treatment are standard [4][5] Industry Insights - Currently, there are no approved treatments specifically for HR-SMM, with an estimated 35,000 new multiple myeloma cases expected in the U.S. in 2024, of which approximately 15% are classified as smoldering [3][7] - The standard of care for smoldering multiple myeloma is active monitoring, which may delay therapeutic intervention until significant disease progression occurs [3][8] - The AQUILA study, a Phase 3 trial, demonstrated that early intervention with DARZALEX FASPRO® could reduce the risk of progression or death in patients with HR-SMM [4][6]